aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-12-08 14:00Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant stock price decline after the failure of a key clinical study [1][2]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly regarding the drug's ability to allow patients to taper off steroids completely [1]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48 [1]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of aTyr during the specified class period are encouraged to register for the class action, with a deadline set for December 8, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [3].